Internal Medicine, Hematology & Oncology · Shreveport, LA
NPI
1093926446
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1501 Kings Hwy
Shreveport, LA, 71103
Phone (318) 675-5000
Groups this clinician bills Medicare through
Medicare paid, 2024
$102K
1,488 services
Medicare patients, 2024
502
Average age 74
Drug cost, 2024
$4.7M
3,030 prescriptions
Company payments, 2025
$141K
From 40 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Prakash Peddi was code 99214 (office e&m - established), 1,102 times for 369 patients. In total Prakash Peddi billed 1,488 services in 12 codes, and Medicare paid $102K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-07-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 1,102 | 369 | $65.49 | $72K |
| 99213 Office E&M - Established | Facility | 122 | 101 | $38.98 | $4,756 |
| 99205 Office E&M - New | Facility | 62 | 62 | $117.87 | $7,308 |
| 99215 Office E&M - Established | Facility | 56 | 43 | $100.37 | $5,621 |
| 99232 Hospital E&M - Subsequent | Facility | 44 | 25 | $58.94 | $2,593 |
| 99233 Hospital E&M - Subsequent | Facility | 33 | 28 | $88.64 | $2,925 |
| 99214 Office E&M - Established | Office | 28 | 24 | $62.40 | $1,747 |
| 99223 Hospital E&M - Initial | Facility | 24 | 24 | $129.73 | $3,114 |
By year: 2022 $129K for 1,468 services; 2023 $116K for 1,590 services; 2024 $102K for 1,488 services.
Medicare prescription drug claims, 2024
In 2024, the drug Prakash Peddi prescribed most often to Medicare patients was Letrozole, with 851 prescriptions and refills. In total Prakash Peddi wrote 3,030 Medicare prescriptions that cost $4.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 851 | 1,867 | 218 | $16K |
| Acyclovir Generic | 166 | 209 | 48 | $1,650 |
| Pantoprazole Sodium Generic | 161 | 242 | 51 | $1,119 |
| Tamoxifen Citrate Generic | 149 | 379 | 45 | $3,390 |
| Prednisone Generic | 144 | 156 | 29 | $509 |
| Ondansetron Hcl Generic | 114 | 117 | 54 | $1,155 |
| Gabapentin Generic | 101 | 125 | 24 | $604 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 84 | 148 | 21 | $1,445 |
| Abiraterone Acetate Generic | 81 | 81 | Under 11 | $322K |
| Kisqali Ribociclib Succinate | 68 | 68 | 14 | $928K |
| Metoclopramide Hcl Generic | 68 | 68 | 29 | $212 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 61 | 61 | 21 | $1,142 |
| Anastrozole Generic | 61 | 141 | 19 | $1,067 |
| Kisqali Femara Co-Pack Ribociclib Succinate/Letrozole | 55 | 55 | Under 11 | $935K |
| Eliquis Apixaban | 54 | 54 | 11 | $31K |
Brand drugs: 432 claims; generic drugs: 2,598 claims; opioid claims: 105.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Prakash Peddi $141K ($141K in general payments such as food, travel and fees) from 40 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $48K.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 37 | $48K |
| Gilead Sciences, Inc. GILD | 33 | $40K |
| Daiichi Sankyo Inc. 4568.T | 27 | $30K |
| Stemline Therapeutics Inc. | 16 | $19K |
| Novartis Pharmaceuticals Corporation NVS | 38 | $1,489 |
| Merck Sharp & Dohme LLC MRK | 10 | $303 |
| Janssen Biotech, Inc. JNJ | 7 | $225 |
| Abbvie Inc. ABBV | 6 | $183 |
| GlaxoSmithKline, LLC. GSK | 8 | $172 |
| EMD Serono, Inc. MRK.DE | 6 | $157 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.